Corporate Banner
Satellite Banner
Genotyping & Gene Expression
Scientific Community
Become a Member | Sign in
Home>News>This Article

Cancer Research UK Purchases Fluidigm Genotyping System

Published: Friday, June 05, 2009
Last Updated: Friday, June 05, 2009
Bookmark and Share
The research centre will utilize high-throughput SNP genotyping to identify and verify genetic variants underlining susceptibility to various cancers.

Fluidigm Europe has announced that the Cancer Research UK Centre for Genetic Epidemiology, University of Cambridge, based at Strangeways Research Laboratory, has purchased the company's EP1 System to conduct cancer research and disease association studies.

The Fluidigm EP1 system combines the efficiencies of integrated fluidic circuit (IFC)-based high-throughput genotyping in a desktop-sized configuration.

The Centre for Genetic Epidemiology is using high-throughput SNP genotyping to identify and verify genetic variants that can underlie susceptibility to various cancers. Cancers that are being investigated include breast, ovarian, colorectal, prostate, and melanoma. The lab uses an automated process with sample tracking and quality control. The Centre has successfully completed its validation experiments on the EP1 system using real samples and will now move forward using the system in its large genotyping studies.

"The Centre for Genetic Epidemiology is undertaking important research focusing on understanding the determinants of common disease and how to prevent them. Their work can make a noteworthy difference in people's lives," said Gajus Worthington, Fluidigm president and chief executive officer. "We believe the attributes of our EP1 system can help them speed toward the answers they seek."

Strangeways Research Laboratory is known for its exploration surrounding identification and prevention of common diseases with a genetic component. They use a wide range of disciplines relevant to a given field, and bring together researchers in epidemiology, molecular genetics, bioinformatics, statistics and public health. This interdisciplinary approach is a particular strength of Strangeways Research Laboratory.

Fluidigm's EP1 system, combined with the company's IFCs called dynamic arrays, provide superior data quality, an easy workflow, and cost savings for high-throughput SNP genotyping studies. The EP1 system is designed to deliver the highest quality SNP genotyping results on the market with better than 99 percent call rates and 99.75 percent or greater accuracy, Fluidigm says.

The EP1 system, which includes the IFC Controller, Stand-Alone Thermal Cycler and End Point Reader, provides over 27,000 genotypes a day. By adding more IFC controllers and thermal cyclers to be used in conjunction with a single EP1 Reader, laboratories can generate more than 200,000 genotypes in a day using TaqMan chemistries.

Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,800+ scientific posters on ePosters
  • More than 4,000+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Fluidigm, OpGen Collaborate
Fluidigm and OpGen have announced an agreement to collaborate on instruments and kits to test for multi-drug resistance genes in bacteria, fungi, and viruses.
Tuesday, July 14, 2015
Fluidigm to Acquire DVS Sciences
The acquisition consideration of approximately $207.5 million consists of a combination of Fluidigm common stock and cash.
Wednesday, January 29, 2014
Singapore Single-Cell Research Centre Opens Door for Asian Biological Discoveries
Centre dedicated to diagnosis and treatment derived from single-cell exploration.
Monday, April 29, 2013
Fluidigm Announces $60 Million Public Offering of Common Stock
Company has closed the previously announced underwritten public offering of 4,209,000 shares of its common stock at a price to the public of $14.25 per share for gross proceeds of approximately $60 million.
Wednesday, August 22, 2012
Leading Leukemia Lab Invests In Fluidigm Access Array™ and EP1™ Systems
Fluidigm Corporation has announced that MLL Munich Leukemia Laboratory ( has purchased Access Array™ and EP1™ Systems.
Tuesday, November 16, 2010
Chinese University of Hong Kong Selects Fluidigm’s BioMark™ System for Molecular Diagnostic Applications
The University will use the system to detect and quantify viruses associated with cancer as well as for research on other molecular diagnostic applications.
Wednesday, May 23, 2007
Scientific News
NIH Supports New Studies to Find Alzheimer’s Biomarkers in Down Syndrome
Initiative will track dementia onset, progress in Down syndrome volunteers.
New Gene Map Reveals Cancer’s Achilles’ Heel
Team of researchers switches off almost 18,000 genes
Genetic Basis of Fatal Flu Side Effect Discovered
A group of people with fatal H1N1 flu died after their viral infections triggered a deadly hyperinflammatory disorder in susceptible individuals with gene mutations linked to the overactive immune response, according to a recent study.
New Class of RNA Tumor Suppressors Identified
Two short, “housekeeping” RNA molecules block cancer growth by binding to an important cancer-associated protein called KRAS. More than a quarter of all human cancers are missing these RNAs.
Mathematical Model Forecasts the Path of Breast Cancer
Chances of survival depend on which organs breast cancer tumors colonize first.
Ancient Viral Molecules Essential for Human Development
Genetic material from ancient viral infections is critical to human development, according to researchers at the Stanford University School of Medicine.
Measuring microRNAs in Blood to Speed Cancer Detection
A simple, ultrasensitive microRNA sensor holds promise for the design of new diagnostic strategies and, potentially, for the prognosis and treatment of pancreatic and other cancers.
Personalized Drug Screening for Multiple Myeloma Patients
A personalized method for testing the effectiveness of drugs that treat multiple myeloma may predict quickly and more accurately the best treatments for individual patients with the bone marrow cancer.
Metabolic Profiles Distinguish Early Stage Ovarian Cancer with Unprecedented Accuracy
Studying blood serum compounds of different molecular weights has led scientists to a set of biomarkers that may enable development of a highly accurate screening test for early-stage ovarian cancer.
New Way to Force Stem Cells to Become Bone Cells
Potential therapies based on this discovery could help people heal bone injuries or set hardware, such as replacement knees and hips.
Skyscraper Banner

SELECTBIO Market Reports
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,800+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,000+ scientific videos